Evidence map›Paper›PMID 39613902›Full record

ArticleJournal of clinical immunology2024

Nationwide Survey of Multisystem Inflammatory Syndrome in Children Associated with Coronavirus Disease 2019 in Japan.

Daisuke Matsubara, Yuri Matsubara, Mamoru Ayusawa, Hiromichi Hamada, Mitsuru Seki, Hiroyuki Yamagishi, Yoshihide Mitani, Yoshihiro Onouchi, Hiroyuki Moriuchi, Isao Miyairi and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of clinical immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Daisuke Matsubara *Department of Pediatrics, Jichi Medical University, 3311-1 Shimotsuke, Tochigi, 329-0498, Japan. 99081dm@jichi.ac.jp.ORCID http://orcid.org/0000-0002-4115-7640
Yuri Matsubara *Division of Public Health, Center for Community Medicine, Jichi Medical University, Tochigi, Japan.
Mamoru AyusawaDepartment of Pediatrics and Child Health, Nihon University School of Medicine, Tokyo, Japan.
Hiromichi HamadaDepartment of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan.
Mitsuru SekiDepartment of Pediatrics, Jichi Medical University, 3311-1 Shimotsuke, Tochigi, 329-0498, Japan.
Hiroyuki YamagishiDepartment of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
Yoshihide MitaniDepartment of Pediatrics, Mie University Graduate School of Medicine, Mie, Japan.
Yoshihiro OnouchiDepartment of Public Health, Chiba University Graduate School of Medicine, Chiba, Japan.
Hiroyuki MoriuchiDepartment of Pediatrics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Isao MiyairiDepartment of Pediatrics, Hamamatsu University School of Medicine, Shizuoka, Japan.
Keiko Tanaka-TayaKanagawa Prefectural Institute of Public Health, Kanagawa, Japan.
Tomohiro KatsutaDepartment of Pediatrics, St. Marianna University School of Medicine, Kanagawa, Japan.
Hiroshi KurosawaDepartment of Pediatric Critical Care Medicine, Hyogo Prefectural Kobe Children's Hospital, Hyogo, Japan.
Kazunori AokiDepartment of Pediatric Critical Care Medicine, Hyogo Prefectural Kobe Children's Hospital, Hyogo, Japan.
Naoki ShimizuDepartment of Pediatrics, St. Marianna University School of Medicine, Kanagawa, Japan.
Yosikazu NakamuraUtsunomiya Public Health Center, Tochigi, Japan.

Funding

Japan Agency for Medical Research and Development JP22fk0108514
6 · The paper itself

Abstract

backgroundMultisystem inflammatory syndrome in children (MIS-C) presents some clinical overlap with Kawasaki disease (KD). Although KD is common in Japan, the clinical characteristics of MIS-C in Japan remain unknown. Therefore, we aimed to determine the epidemiological and clinical features of MIS-C in Japan.

methodsUsing a case reporting form, a nationwide registry was created between November 2020 and March 2023, involving 2,080 facilities throughout Japan. We prospectively and retrospectively enrolled patients with MIS-C. The primary outcomes were the number and incidence rates of children with MIS-C. The secondary outcomes included clinical features, such as KD phenotype, organ involvement, shock, intensive care unit admission, and coronary artery lesions.

resultsAmong 398 patients registered, central review identified 129 MIS-C cases (mean age: 8·8 ± 3·7 years). The overall incidence rate was estimated to be 1·5 per 100,000 COVID-19 cases, exhibiting a decline as the COVID-19 pandemic progressed, from 12·3 cases (Pre-Delta) to 1·3 cases (Omicron); 80% of MIS-C cases occurred during the Omicron variant predominant period, and 72% of children with MIS-C met the KD criteria. Cardiovascular (88%) and gastrointestinal (90%) involvement were frequent. In Japan, MIS-C cases showed comparatively less severe clinical features, with shock in 29% and admission to the intensive care unit in 12% of cases. Coronary artery lesions were identified in 15 cases (11·6%), irrespective of the presence of shock. No fatalities were reported.

conclusionThe incidence of MIS-C was low in Japan. The clinical features distinctively exhibited a more KD-like phenotype, with less severe clinical features.

Indexed as

COVID-19Mucocutaneous Lymph Node SyndromeRegistriesSARS-CoV-2Systemic Inflammatory Response SyndromeAdolescentChildChild, PreschoolFemaleHumansIncidenceInfantJapanMaleRetrospective StudiesCOVID-19incidenceKawasaki diseasemultisystem inflammatory syndrome in children

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.